On December 23, SCL Science, a digital healthcare specialist, announced that it will accelerate the expansion of its bio-logistics business by acquiring the Honam region bio-logistics operations from the Seoul Clinical Laboratories (SCL) Foundation.
This acquisition, valued at 4.3 billion won, follows SCL Science's earlier acquisition of the Yeongnam region bio-logistics business announced in July of this year. Bio-logistics is a core function of medical infrastructure, involving the transportation of specimens collected from medical institutions to testing laboratories under strict management.
A representative from SCL Science stated, "The company already possesses a computerized management system that meets the demands of the bio-logistics delivery market, where strict temperature control and timely delivery are crucial." The representative added, "We expect this business acquisition to generate an additional annual revenue of approximately 5 billion won."
The company previously announced in its quarterly report for September this year that it achieved its first-ever quarterly operating profit, reflecting the results of the acquired business. SCL Science plans to establish a sustainable profit structure through simultaneous growth in service areas and sales scale, and will continue to pursue high value-added business initiatives, including the advancement of bio-logistics services.
Based on its bio-logistics and digital capabilities, SCL Science is also building a comprehensive bio-platform that covers the entire healthcare sector, including advanced precision medical technologies such as cancer vaccines and genetic testing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
